Evidence map›Paper›PMID 37274644›Full record

ArticleHeliyon2023

Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy.

Giovanni Antonini, Francesco Habetswallner, Maurizio Inghilleri, Renato Mantegazza, Carmelo Rodolico, Francesco Saccà, Manlio Sgarzi, Femke deRuyck, Sandra Paci, Glenn Phillips and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Article
  8. Article
  9. Disease changes and cost analysis of myasthenia gravis: a 10 years retrospective study from a reference center in Italy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Giovanni AntoniniDepartment of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, University of Rome La Sapienza, Rome, Italy.
Francesco HabetswallnerClinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
Maurizio InghilleriNeuromuscular Disorders Unit, Department of Human Neurosciences, Sapienza University, Rome, Italy.
Renato MantegazzaNeurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Carmelo RodolicoNeurology and Neuromuscular Disorders Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Francesco SaccàNSRO Department, University of Naples Federico II, Napoli, Italy.
Manlio SgarziDepartment of Neurology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Femke deRuyckArgenx BVBA, Zwijnaarde, Belgium.
Sandra PaciArgenx BVBA, Zwijnaarde, Belgium.
Glenn PhillipsArgenx Inc., Boston, USA.
Laura CrippaRAReg S.r.l., Cesano Maderno, Italy.
Chiara VeronesiCliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy.
Valentina PerroneCliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy.
Luca Degli EspostiCliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy.
LHU study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to investigate the epidemiology, management, and economic burden of myasthenia gravis in settings of real clinical practice. The analysis used administrative databases covering around 12 million subjects across Italy and included all adult patients with hospitalization discharge diagnosis or active exemption code for myasthenia gravis or with ≥1 pyridostigmine prescription from 2011 to 2018. The estimated prevalence of myasthenia gravis during 2018 was in the range 13.5-29.3/100,000 people (depending on the criteria applied), corresponding to 8190-17,728 alive patients, when reproportioning data to the entire Italian population. Overall 4397 patients with myasthenia gravis (mean age 61.7 years, 46.6% males) were included. A large pyridostigmine use was observed (84.0%-46.8% from 1st to 3rd year of follow-up), followed by corticosteroids (54.5%-44.6% from 1st to 3rd year of follow-up) and non-steroidal immunosuppressants (16% over follow-up). Total direct healthcare costs for myasthenia gravis were 4-times higher than those of the general population (€3771 and €869, respectively), and up to 9-fold increased when considering patients with exacerbation (€7827). These findings showed the epidemiologic burden of myasthenia gravis and the complexity of the therapeutic management for the affected patients, with large use of treatments and elevated healthcare expenditures.

Indexed as

Administrative databasesEpidemiologyHealthcare resource consumptionMyasthenia gravisPyridostigmineReal word evidence

Identifiers

PMID37274644
PMCPMC10238888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.